NCT07293468 2025-12-19
BIIRTH
Tuen Mun Hospital
Phase 2/3 Recruiting
Clinical Trials
10 trialsNCT04776655 2025-10-02
LIBImAb
Azienda USL Reggio Emilia - IRCCS
Phase 3 Recruiting
NCT07128251 2025-08-17
A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
Anhui Provincial Hospital
Phase 2 Not yet recruiting
NCT07070713 2025-07-17
Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06293014 2024-03-05
TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer
Henan Cancer Hospital
Phase 2 Recruiting
NCT05640726 2022-12-07
The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT05314101 2022-08-23
TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT03380689 2021-03-08
SIRB2
Fujian Cancer Hospital
Phase 1 Withdrawn
NCT00450203 2016-12-01
ST03
Medical Research Council
Phase 2/3 Unknown
NCT01249521 2010-11-30
Vengeance
Austin Health
Phase 2 Unknown